Wednesday, June 10, 2026

pharma Β· Critical Limb Ischemia (CLI) Β· Sarcoma Β· DSGN

Lxo Ireland Designated

Lxo Ireland Designated clinical programs β€” 68 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CARLSBAD, CA, IE HQ
Public company Type
DSGN Β· NYSE Ticker
Company details
Intelligence Β· Clinical Programs

Lxo Ireland Designated projects

68 ClinicalTrials.gov programs sponsored by Lxo Ireland Designated.

Lxo Ireland Designated has 68 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. Allo-depleted lymphocyte infusion

    Lxo Ireland Designated Activity Company

    Transplant-Related Hematologic Malignancy

    phase 1 other terminated

    1 trial
  2. CEA protein antigen plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Rectal Cancer

    phase 1 mab active

    1 trial
  3. Carfilzomib

    Lxo Ireland Designated Activity Company

    Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule completed

    1 trial
  4. DT-216

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 1 small molecule completed

    2 trials
  5. GLA-AF

    Lxo Ireland Designated Activity Company

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  6. GLA-SE

    Lxo Ireland Designated Activity Company

    Merkel Cell Carcinoma

    phase 1 mab completed

    1 trial
  7. HSV 2 Formulation 1

    Lxo Ireland Designated Activity Company

    Genital Herpes

    phase 1 mab terminated

    1 trial
  8. ID-LV305

    Lxo Ireland Designated Activity Company

    Melanoma - Currently Enrolling

    phase 1 mab completed

    1 trial
  9. IDC-G305

    Lxo Ireland Designated Activity Company

    Melanoma

    phase 1 mab completed

    1 trial
  10. IND 179135 Research

    Lxo Ireland Designated Activity Company

    HIV Infections

    phase 1 mab active

    1 trial
  11. IND165646

    Lxo Ireland Designated Activity Company

    Covid19

    phase 1 mab active

    1 trial
  12. Infudopa i.v.

    Lxo Ireland Designated Activity Company

    Parkinson Disease

    phase 1 small molecule completed

    1 trial
  13. MSD-001

    Lxo Ireland Designated Activity Company

    Mental Health Disorders

    phase 1 small molecule completed

    1 trial
  14. Novel restraint

    Lxo Ireland Designated Activity Company

    Acute Respiratory Failure

    phase 1 other completed

    1 trial
  15. Switch active lifestyles brought to you by MediaWise

    Lxo Ireland Designated Activity Company

    Overweight

    phase 1 other completed

    1 trial
  16. Hyperbaric bupivacaine+Sufentanil

    Lxo Ireland Designated Activity Company

    Anesthesia; Functional

    approved small molecule completed

    1 trial
  17. Low intensity laser for oral mucositis

    Lxo Ireland Designated Activity Company

    Oral Mucositis

    approved other active

    1 trial
  18. Pre-dilation side branch

    Lxo Ireland Designated Activity Company

    Coronary Angiography

    approved other completed

    1 trial
  19. Roflumilast alternated days

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease (COPD)

    approved small molecule completed

    1 trial
  20. Subcutaneous glargine insulin

    Lxo Ireland Designated Activity Company

    Diabetes Mellitus

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Lxo Ireland Designated have?

68 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.